바로가기메뉴

본문 바로가기 주메뉴 바로가기

Tuberculosis & Respiratory Diseases

Article Contents

Prev Next
e-Submission

Vol.64 No.3
Citation Share

Prognostic Value of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) Expression in Resected Non-small Cell Lung Cancer

Tuberculosis & Respiratory Diseases / Tuberculosis & Respiratory Diseases,
2008, v.64 no.3, pp.200-205

















& (2008). Prognostic Value of Vascular Endothelial Growth Factor (VEGF) and Basic Fibroblast Growth Factor (bFGF) Expression in Resected Non-small Cell Lung Cancer. Tuberculosis & Respiratory Diseases, 64(3), 200-205.
  • Downloaded
  • Viewed
PDF Download

Abstract

Background: Tumor angiogenesis plays an important role in tumor growth, maintenance and metastatic potential. Tumor tissue produces many types of angiogenic growth factors. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) have both been implicated to have roles in tumor angiogenesis. In this study, the expression of tissue VEGF and bFGF from non-small cell lung cancer (NSCLC) patients were analyzed. Methods: We retrospectively investigated 35 patients with a histologically confirmed adenocarcinoma or squamous cell carcinoma of the lung, where the primary curative approach was surgery. An ELISA was employed to determine the expression of VEGF and bFGF in extracts prepared from 35 frozen tissue samples taken from the cancer patients. Results: VEGF and bFGF concentrations were significantly increased in lung cancer tissue as compared with control(non-cancerous) tissue. The VEGF concentration was significantly increased in T2 and T3 cancers as compared with T1 cancer. Expression of VEGF was increased in node-positive lung cancer tissue as compared with node-negative lung cancer tissue (p=0.06). VEGF and bFGF expression were not directly related to the stage of lung cancer and patient survival. Conclusion: Expression of VEGF and bFGF were increased in lung cancer tissue, and the expression of VEGF concentration in lung cancer tissue was more likely related with tumor size and the presence of a lymph node metastasis than the expression of bFGF. However, in this study, expression of both VEGF and bFGF in tissue were not associated with patient prognosis.

keywords
VEGF, bFGF, Angiogenesis, Lung cancer, Prognosis

Reference

1.

1. Choi Y, Kim Y, Hong YC, Park SK, Yoo KY. Temporal changes of lung cancer mortality in Korea. J Korean Med Sci 2007;22:524-8.

2.

2. Ravdin PM, Davis G. Prognosis of patients with resected non-small cell lung cancer: impact of clinical and pathologic variables. Lung Cancer 2006;52:207-12.

3.

3. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006;51:143-58.

4.

4. Onn A, Herbst RS. Angiogenesis and lung cancer: implications for prognosis and treatment. Lancet Oncol 2007;8:460-1.

5.

5. Anderson IC, Mari SE, Broderick RJ, Mari BP, Shipp MA. The angiogenic factor interleukin 8 is induced in non-small cell lung cancer/pulmonary fibroblast cocultures. Cancer Res 2000;60:269-72.

6.

6. Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T.Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC. Eur J Cardiothorac Surg 2004;25:443-8.

7.

7. Papetti M, Herman IM. Mechanisms of normal and tumor-derived angiogenesis. Am J Physiol Cell Physiol 2002;282:C947-70.

8.

8. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005;94:209-31.

9.

9. Folkman J. Tumor angiogenesis: therapeutic implications.N Engl J Med 1971;285:1182-6.

10.

10. Leung DW, Cachianes G, Kuang WJ, Goeddel DV,Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989;246:1306-9.

11.

11. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005;69 Suppl 3:4-10.

12.

12. Cebe-Suarez S, Zehnder-Fjallman A, Ballmer-Hofer K.The role of VEGF receptors in angiogenesis: complex partnerships. Cell Mol Life Sci 2006;63:601-15.

13.

13. Kiselyov A, Balakin KV, Tkachenko SE. VEGF/VEGFR signalling as a target for inhibiting angiogenesis. Expert Opin Investig Drugs 2007;16:83-107.

14.

14. Szebenyi G, Fallon JF. Fibroblast growth factors as multifunctional signaling factors. Int Rev Cytol 1999;185:45-106.

15.

15. Klagsbrun M. Mediators of angiogenesis: the biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Semin Cancer Biol 1992;3:81-7.

16.

16. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci 2001;22:201-7.

17.

17. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-5.

18.

18. Lee SN. The prognostic role of vascular endothelial growth factor (VEGF) expression and angiogenesis in curatively resected non-small cell lung cancer. J Korean Cancer Assoc 1999;31:1210-8.

19.

19. Ko HJ, Park JH, Shim H, Yang SH, Jeong ET.Prognostic value of vascular endothelial growth factor(VEGF) in resected non-small cell lung cancer. Tuberc Respir Dis 2001;50:676-85.

20.

20. Hemmerlein B, Kugler A, Ozisik R, Ringert RH, Radzun HJ, Thelen P. Vascular endothelial growth factor expression,angiogenesis, and necrosis in renal cell carcinomas. Virchows Arch 2001;439:645-52.

21.

21. Rong Y, Durden DL, Van Meir EG, Brat DJ. 'Pseudopalisading'necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia,and angiogenesis. J Neuropathol Exp Neurol 2006;65:529-39.

Tuberculosis & Respiratory Diseases

e-Submission OA Policy